应用蛋白芯片技术筛选肺腺癌化疗敏感血清蛋白标志物

Screening on the serum protein markers for predicting lung adenocarcinoma chemotherapy sensitivity with the SELDI -TOF- MS technique

目的 探讨肺腺癌化疗敏感患者与化疗耐药患者血清蛋白质质谱的不同，筛选肺腺癌化疗敏感血清蛋白标志物。方法用WCX2蛋白芯片结合表面增强激光解析电离飞行时间质谱（SELDI—TOF—MS）技术，检测22例肺腺癌化疗敏感的患者和21例化疗不敏感的血清蛋白质谱，筛选出差异表达蛋白质。结果发现利用M／Z（质荷比）为16083．50Da，7963．17Da，16121．50Da，15921．60Da，8066．79Da，8040．17Da和3394．57Da的7个差异蛋白可区分标准含铂类方案化疗敏感组和耐药组，联合m／z为7963．17Da与16083．50Da的差异蛋白建立预测模型，可预测肺腺癌标准含铂类方案化疗敏感／耐药性，其敏感性86．36％和特异性80．95％。结论SELDI—TOF—MS技术是寻找肺腺癌化疗敏感血清诊断标志物的有效工具。

Objective To explore the difference of serum protein mass spectrometry between the sensitive and drug resistance lung adenocarcinoma patients, and to discover serum protein markers for predicting chemotherapy sensitivity of lung adenocarcinoma patients. Methods To detect the protein mass spectrometry of 22 chemosensitive lung adenoearcinoma patients and 21 chemotherapy - resistant cases with WCX2 protein chip combining with SELDI - TOF - MS technique, and then screen differentially expressed proteins. Results In this experiment,7 differentially expressed proteins were screened, which can differentiate the chemosensitive or the chemotherapyresistant patients with standard platinum - based chemotherapy. The m/z value of them is 16 083.50 Da,7 963.17 Da, 16 121.50 Da, 15 921.60 Da,8 066.79 Da,8 040.17 Da and 3 394.57 Da respectively. Predictive model with M/Z 7 963.17 Da and 16 083.50 Da could differentiate the ehemosensitive or the chemotherapy - resistant patients ,whose sensitivity was 86.36% and specificity was 80.95%. Conclusions SELDI - TOF - MS is an effective instrument to find sensitive serum marker for predicting lung adenocareinoma chemotherapy sensitivity.